Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes' - 2Famous Rough terrain Vehicles for 2024
- 3This Week In Space podcast: Episode 189 — Privatizing Orbit
- 42024's Hot Games: Must-Play Titles of the Year
- 5Journey Travel Objections for Your Next Experience
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Picking the Right Home Machines: A Commonsense Aide
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Monetary Freedom Guide: Plan Your Future
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Find the Future of Outsourcing: Exploring the Gig Economy
